Table 5 Baseline characteristics of the CHC patients with an SVR with baseline glucose levels ≥ 5.6.
Parameters | All (N = 332) | Improved (N = 182) | Unimproved (N = 150) | P - valuea |
|---|---|---|---|---|
Male | 173(52.1%) | 96(52.7%) | 77(51.3%) | 0.797 |
Age, years | 51(44–61) | 49(41–59.25) | 54(46.75–62) | 0.004b |
Genotype | ||||
1 | 217(65.4%) | 116(63.7%) | 101(67.3%) | 0.604 |
2 | 11(3.3%) | 5(2.7%) | 6(4%) | |
3 | 27(8.1%) | 14(7.7%) | 13(8.7%) | |
Others and unknown | 77(23.2%) | 47(25.8%) | 30(20%) | |
HCV-RNA, log IU/mL | 6.07(5.17–6.55) | 6.06(4.95–6.56) | 6.08(5.31–6.56) | 0.460 |
GLU, mmol/L | 6.22(5.84–6.94) | 6.05(5.75–6.88) | 6.38(5.99–7.62) | <0.001b |
Prediabetes | 250(75.3%) | 139(76.4%) | 111(74%) | 0.618 |
Diabetes | 82(24.7%) | 43(23.6%) | 39(26%) | |
TBiL, umol/L | 16.65(11.82–21.67) | 15.50(12.05–21.22) | 17.90(11.70–22.75) | 0.190 |
ALT, IU/L | 56.50(33.00–110.75) | 56.00(32.00–103.00) | 58.00(37.00–123.25) | 0.515 |
AST, IU/L | 54.00(33.00–90.00) | 52.00(32.75–86.25) | 54.50(33.00–92.25) | 0.435 |
ALB, g/L | 43.80(40.72–46.60) | 43.90(41.00–46.80) | 43.60(40.25–46.50) | 0.472 |
ALP, IU/L | 85.00(69.00–110.00) | 82.00(68.00–105.25) | 92.00(71.00–122.25) | 0.024b |
GGT, IU/L | 41.50(26.00–93.25) | 42.50(25.75–83.75) | 40.50(25.75–96.25) | 0.824 |
Hb, g/L | 141.00(126.00–153.00) | 141.00(127.00–154.25) | 137.50(125.00–153.00) | 0.388 |
PLTs, 109/L | 114.00(77.25–153.25) | 118.50(84.50–166.50) | 108.50(73.00–142.25) | 0.014b |
WBCs, 109/L | 5.24(4.13–6.52) | 5.36(4.27–6.59) | 4.93(3.91–6.48) | 0.118 |
APRI | 1.23(0.65–2.61) | 1.05(0.63–2.18) | 1.41(0.69–3.04) | 0.036b |
FIB-4 | 3.43(1.94–6.01) | 3.13(1.81–5.21) | 3.93(2.30–7.36) | 0.003b |
